- Home
- YXT vs ACRS Comparison
YXT vs ACRS Comparison
Compare YXT & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YXT
- ACRS
- Stock Information
- Founded
- YXT 2011
- ACRS 2012
- Country
- YXT China
- ACRS United States
- Employees
- YXT N/A
- ACRS N/A
- Industry
- YXT
- ACRS Biotechnology: Pharmaceutical Preparations
- Sector
- YXT
- ACRS Health Care
- Exchange
- YXT NYSE
- ACRS Nasdaq
- Market Cap
- YXT 129.2M
- ACRS 132.0M
- IPO Year
- YXT 2024
- ACRS 2015
- Fundamental
- Price
- YXT $2.31
- ACRS $2.72
- Analyst Decision
- YXT
- ACRS Strong Buy
- Analyst Count
- YXT 0
- ACRS 5
- Target Price
- YXT N/A
- ACRS $8.75
- AVG Volume (30 Days)
- YXT 85.1K
- ACRS 1.1M
- Earning Date
- YXT 11-26-2024
- ACRS 11-06-2024
- Dividend Yield
- YXT N/A
- ACRS N/A
- EPS Growth
- YXT N/A
- ACRS N/A
- EPS
- YXT 3.06
- ACRS N/A
- Revenue
- YXT $48,030,651.00
- ACRS $27,079,000.00
- Revenue This Year
- YXT N/A
- ACRS N/A
- Revenue Next Year
- YXT N/A
- ACRS N/A
- P/E Ratio
- YXT $0.75
- ACRS N/A
- Revenue Growth
- YXT N/A
- ACRS 26.35
- 52 Week Low
- YXT $1.90
- ACRS $0.86
- 52 Week High
- YXT $11.00
- ACRS $5.17
- Technical
- Relative Strength Index (RSI)
- YXT N/A
- ACRS 41.17
- Support Level
- YXT N/A
- ACRS $2.91
- Resistance Level
- YXT N/A
- ACRS $3.29
- Average True Range (ATR)
- YXT 0.00
- ACRS 0.29
- MACD
- YXT 0.00
- ACRS -0.18
- Stochastic Oscillator
- YXT 0.00
- ACRS 0.75
About YXT YXT.COM GROUP HOLDING LIMITED SPON ADS EA REP 3 CL A SHS
Yxt.Com Group Holding Ltd operates as a technology company. The company has created a SaaS model that integrates software and content, assisting customers in the digital transformation of corporate learning. The company operates in the People's Republic of China.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases. The contract research segment earns revenue from the provision of laboratory services. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.